COMETRIQ Cabozantinib Capsules

DESCRIPTION

Cometriq (cabozantinib) is a prescription medicine used to treat people with medullary thyroid cancer (MTC) which has spread to other parts of the body (called metastatic MTC).

Manufacturer :  Exelixis, Inc.

ADDITIONAL INFORMATION

Strengths available :  100mg & 140mg

Form : Capsules

FDA  Approved :  US FDA Approved

Date of Approval  :  November 29th, 2012

Storage : Store at room temperature between 20° C – 25° C

Dosage :  

Recommended Dose-

Do NOT substitute COMETRIQ capsules with cabozantinib tablets.

The recommended daily dose of COMETRIQ is 140 mg (one 80-mg and three 20-mg capsules). Do not administer COMETRIQ with food. Instruct patients not to eat for at least 2 hours before and at least 1 hour after taking COMETRIQ. Continue treatment until disease progression or unacceptable toxicity occurs.

Swallow COMETRIQ capsules whole. Do not open COMETRIQ capsules.

Do not take a missed dose within 12 hours of the next dose.

Do not ingest foods (e.g., grapefruit, grapefruit juice) or nutritional supplements that are known to inhibit cytochrome P450 while taking COMETRIQ.

SIDE EFFECTS

Serious side effects may be Blood clots, Stroke, Heart attack, and Chest pain , Swelling or pain in your arms or legs, Shortness of breath, Feel lightheaded or faint, Sweating more than usual, numbness or weakness of your face, arm or leg, especially on one side of your body, sudden confusion, trouble speaking or understanding, sudden trouble seeing in one or both eyes, sudden trouble walking, dizziness, loss of balance or coordination, a sudden severe headache

PACK SIZE

7 x 20 mg  or 7 x 80 mg Capsules

Reviews

There are no reviews yet.

Be the first to review “COMETRIQ Cabozantinib Capsules”

Your email address will not be published. Required fields are marked *